Europe Small Molecule Innovator Cdmo Market Size & Outlook
Europe small molecule innovator cdmo market, 2018-2030 (US$M)
Related Markets
Europe small molecule innovator cdmo market highlights
- The Europe small molecule innovator cdmo market generated a revenue of USD 9,733.8 million in 2023.
- The market is expected to grow at a CAGR of 6.2% from 2024 to 2030.
- In terms of segment, small molecule api was the largest revenue generating product in 2023.
- Small Molecule API is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 9,733.8 million |
| Market revenue in 2030 | USD 14,847.9 million |
| Growth rate | 6.2% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule api |
| Fastest growing segment | Small Molecule API |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule API, Small Molecule Drug Product |
| Key market players worldwide | Wuxi AppTec Co Ltd, EQT Corp, Thermo Fisher Scientific Inc, Lonza Group Ltd, Catalent Inc, Siegfried Holding AG, Boehringer Ingelheim, Labcorp Holdings Inc, Piramal Pharma Solutions, CordenPharma, Cambrex |
Other key industry trends
- In terms of revenue, Europe region accounted for 20.0% of the global small molecule innovator cdmo market in 2023.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 33,610.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Small Molecule Innovator CDMO Market Scope
Small Molecule Innovator CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe small molecule innovator cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to small molecule innovator cdmo market will help companies and investors design strategic landscapes.
Small molecule api was the largest segment with a revenue share of 61.65% in 2023. Horizon Databook has segmented the Europe small molecule innovator cdmo market based on small molecule api, small molecule drug product covering the revenue growth of each sub-segment from 2018 to 2030.
Europe held the third-largest share of the global market in 2023. The pharmaceutical industry in the region is robust, with many companies involved in drug development, discovery, and manufacturing. It is anticipated that the increasing number of initiatives being undertaken by pharmaceutical companies will enhance the need for CDMOs.
Furthermore, the growing trend of outsourcing services to European nations is expected to support the rise in demand for small molecule innovator CDMOs. Furthermore, various factors expected to boost market growth during the forecast period include the growing prevalence of rare diseases.
Similar changes in market scenarios are anticipated at a rapid rate due to the trend of drug discovery and emerging R&D activities. Many of the leading CDMOs of the world such as Lonza, Cambrex Corporation.
Reasons to subscribe to Europe small molecule innovator cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe small molecule innovator cdmo market databook
-
Our clientele includes a mix of small molecule innovator cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe small molecule innovator cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into Europe small molecule innovator cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Europe small molecule innovator cdmo market size, by country, 2018-2030 (US$M)
Europe Small Molecule Innovator CDMO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
